Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03304587 · ClinicalTrials.gov registry record · NA
Effects of Bright Light on Co-occurring Cancer-related Symptoms in Breast Cancer Survivors
A NA study, sponsored by Michigan State University.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT03304587: Completed NA study, sponsored by Michigan State University.
NCT03304587 is a NA study that has completed, run by Michigan State University. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03304587, a NA study, has completed, sponsored by Michigan State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study will implement therapeutic bright light that is tailored to the individual's circadian typology and will estimate its effects on circadian rhythms, 4 common cancer-associated symptoms, and impact on quality of life in survivors living with cancer. Examining a selected phase marker (core body temperature) in relation to the associated clinical features (symptoms) is the starting point for future investigation of the biological mechanisms of symptoms.
Primary Outcome
Study participants kept a daily log where they listed the dates and times they used the light visor - noting time they put it on, and the time they took it off. The light exposure were recorded to assess adherence to the treatment protocol. Adherence: percentage that the study participant used the light visor for 30 minutes per day during the 14-day light therapy intervention (based on the daily log that reported use or not use of the light visor for 30 minutes for the 14 days of the interventi
Interventions
- DIAGNOSTIC_TEST Polysomnography (PSG)
- DIAGNOSTIC_TEST Rectal thermistor 400 Series
- OTHER Bright blue-green light
- OTHER Dim red light
- DIAGNOSTIC_TEST Digital foot candle datalogging light meter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-11-06 |
| Est. Completion | 2022-08-31 |
| Phase | NA |
What the finished NCT03304587 record still lists
NCT03304587 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 5 interventions - of which Polysomnography (PSG) is the first listed.
NCT03304587 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03304587 about?
NCT03304587 is a clinical study titled "Effects of Bright Light on Co-occurring Cancer-related Symptoms in Breast Cancer Survivors". This study will implement therapeutic bright light that is tailored to the individual's circadian typology and will estimate its effects on circadian rhythms, 4 common cancer-associated symptoms, and impact on quality of life in survivors living with cancer. Examining a selected phase marker (core b...
What is the current status of trial NCT03304587?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2017-11-06. Estimated completion is 2022-08-31.
What interventions are being tested in trial NCT03304587?
The interventions under investigation include: Polysomnography (PSG) (DIAGNOSTIC_TEST), Rectal thermistor 400 Series (DIAGNOSTIC_TEST), Bright blue-green light (OTHER), Dim red light (OTHER), Digital foot candle datalogging light meter (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03304587?
This trial is sponsored by Michigan State University, which has 120 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03304587's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI